Selank Deep Dive — Anxiety, Cognition, Immune & Gut

Provenance: educational study-synthesis by a licensed MD; data largely Russian (small, unblinded, uncontrolled)

Selank is an approved drug in Russia (anxiety, 2009; OTC, 2017) — but on a different regulatory framework: publicly available trials are <70 patients, not blinded/randomized/controlled, so conclusions (esp. safety) are weaker than EU/US standards. Treat as [educational]/anecdote. Research/educational use only. Source: YouTube — v50r2dl4e84 (Thorough structured capture; full verbatim not stored.)

Identity & tuftsin parentage

Selank is a heptapeptide (7 aa) — a stabilized version of Tuftsin (a 4-aa fragment of immunoglobulin G/IgG) with 3 extra amino acids added for stability. Because it contains the full tuftsin sequence, it inherits tuftsin’s immune effects: tuftsin improves phagocytosis, educates T-cells (cancer surveillance, infection-fighting, self-tolerance), and shifts macrophages from pro-inflammatory M1 → anti-inflammatory M2. (Tuftsin animal data: sepsis survival, fungal infection, autoimmune models — MS/RA/lupus/IBD — and some tumor inhibition; no human in-vivo data.)

Mechanisms of anxiolysis

• GABAergic (chief): helps GABA bind GABA-A like a benzodiazepine — but differently, which likely explains the lack of tolerance/dependence.
• Glutamatergic (NMDA): homeostatic — dampens when over-active (anxiety), can raise when low (cognition).
• Immunomodulatory: anti-inflammatory (M1→M2) → less inflammation-driven anxiety.
• Opioid: inhibits enkephalin breakdown → stress/mood/pain regulation.
• Monoamine balancing: NE/serotonin/dopamine (variable, brain-region/strain dependent).

Human (Russian) evidence

• GAD (20 pts, intranasal): 40% responded rapidly (anxiety −65% in 3 days), 60% gradually (−61% by day 14); EEG changes after a single dose.
• vs benzodiazepines: equal anxiolysis to midazolam (62 pts) and phenazepam (60 pts), plus extra cognitive benefit; crucially effects persisted ~1 week after the last dose and none of the benzo side effects (no sedation/confusion/weakness/memory loss, and no dependence/tolerance/withdrawal). Benzos cause those via GABA-receptor downregulation; Selank’s different GABA-A action + glutamatergic effect likely avoid it.
• Cognition: elderly (15 pts) +10–30% reaction time/attention/short-term memory; weaker evidence than the anxiolytic data.
• Depression/adjustment disorder (30 pts): ↓depression; 2 weeks post-stop, ↓physical symptoms, better nutrition, ↓alcohol misuse.
• Other (mostly animal): pain (enkephalin; morphine synergy), stroke/brain-bleed recovery (one mouse study), gut (stress-ulcer prevention via blood/lymph flow; microbiome — ↑good bacteria, ↓colonic inflammation; brain-gut axis).

Safety / risks

Good Russian anecdotal + OTC safety, no adverse events in (small, short, uncontrolled) studies. Theoretical risks: tolerance/dependence (much less likely than benzos), unknown long-term neuro effects (e.g. BDNF/maladaptive circuits), medication interactions (benzos, GABAergics, opioids, SSRIs/SNRIs, stimulants, alcohol → serotonin-syndrome/sedation risk — use only with close medical monitoring), possible immune dysregulation (it’s a modulator, not stimulant/suppressant — lower risk). Cycle on/off.

Forms, dosing, frequency, cycles

• Forms: intranasal (brain effects — bypasses BBB via cranial-nerve pathways; the Russian-approved/studied form → most safety data → start here) vs subcutaneous (systemic/immune/gut; generally higher systemic bioavailability, though Russian sites claim Selank is 92.8% bioavailable even intranasally — small size + the 3 extra aa resist nasal degradation; unverified). Route can change mechanism (mouse: injectable→GABAergic, intranasal→glutamatergic) → if intranasal underperforms a cycle, the injectable is worth a try.
• Intranasal dose: Russian OTC 300 mcg ×3/day = 900 mcg/day (start); Russian studies used 900 mcg ×3 = 2,700 mcg/day (titrate up to this if needed).
• SubQ dose (no human data): animal 100–300 mcg/kg/day → HED 1 mg/day for 70 kg, but high individual variability → start very low (100 mcg/day), titrate; >500 mcg/day shows diminishing returns, max ~1 mg.
• Frequency: intranasal ~3×/day (short half-life); subQ 1×/day (animal) or 2× if effect wanes. Consistent dosing through the cycle beats single pre-stress doses.
• Cycles: Russian OTC 2 weeks on / 1–3 weeks off; start there, can extend to ~4 on / 2 off.

Use-case verdict

Top peptide for anxiety (strongest mechanism + evidence), especially with comorbid brain fog, autoimmune/inflammatory conditions, recurrent infections, gut issues, or chronic pain. 2nd-tier: depression/adjustment disorder, cognition (after Semax), pain, stroke recovery. 3rd-tier: immune modulation (behind Thymosin Alpha-1), gut (behind BPC-157/KPV).

Candidate note reinforced

• Tuftsin — the endogenous IgG-derived parent tetrapeptide; underlies Selank’s immune effects; genuinely worth its own note.